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Abstract
Background: As a result of the previous part of this trial, many patients with cardiovascular disease were expected
to receive a statin for the first time. In order to provide these patients with comprehensive information on statins,
as recommended by professional guidance, education at first and second dispensing of statins had to be
implemented. This study was designed to assess the effectiveness of an intensive implementation program
targeted at pharmacy project assistants on the frequency of providing education at first dispensing (EAFD) and
education at second dispensing (EASD) of statins in community pharmacies.
Methods: The participating community pharmacies were clustered on the basis of local collaboration, were
numbered by a research assistant and subsequently an independent statistician performed a block randomization,
in which the cluster size (number of pharmacies in each cluster) was balanced. The pharmacies in the control
group received a written manual on the implementation of EAFD and EASD; the pharmacies in the intervention
group received intensive support for the implementation. The impact of the intensive implementation program on
the implementation process and on the primary outcomes was examined in a random coefficient logistic
regression model, which took into account that patients were grouped within pharmacy clusters.
Results: Of the 37 pharmacies in the intervention group, 17 pharmacies (50%) provided EAFD and 12 pharmacies
(35.3%) provided EASD compared to 14 pharmacies (45.2%, P = 0.715) and 12 pharmacies (38.7%, P = 0.899),
respectively, of the 34 pharmacies in the control group. In the intervention group a total of 72 of 469 new statin
users (15.4%) received education and 49 of 393 patients with a second statin prescription (12.5%) compared to 78
of 402 new users (19.4%, P = 0.944) and 35 of 342 patients with a second prescription (10.2%, P = 0.579) in the
control group.
Conclusion: The intensive implementation program did not increase the frequency of providing EAFD and EASD
of statins in community pharmacies.
Trial Registration: clinicaltrials.gov NCT00509717
Background
In October 2006 we started a trial (NCT00509717) in
order to improve the prescribing of statins for patients
with CVD in general practice [1]. As a result of this
trial, many patients with CVD were expected to receive
a statin for the first time. In order to provide these
patients with comprehensive information on statins, as
recommended by professional guidance, education at
first and second dispensing of statins had to be
implemented.
Patient education is a basic element of community
pharmacy practice according to the Dutch Pharmacy
Standard [2] and according to several international
guidelines [3]. Such patient education is required from a
legal and ethical perspective, and it is also recom-
mended to ensure that patients understand how to use
medication safely and effectively [3]. At the time this
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study was designed, providing education at first and sec-
ond dispensing of medication in community pharmacies
was also expected to improve medication adherence and
persistence in the Netherlands, although evidence for
that was scarce. Poor medication adherence or even
total discontinuation of statin therapy for secondary pre-
vention is highly prevalent and an important problem
because it increases mortality and cardiovascular events
[4,5]. Use of statins for secondary prevention rapidly
decreases in the first months, with a gradually smaller
decrease on the longer term [6]. Between 60% and 86%
of the patients still use a statin one year after their first
cardiovascular event [7,8], and between 44% and 80%
after two or more years [6,9-11]. So, enhancing adher-
ence and persistence with statin therapy is important for
optimal secondary prevention of CVD for the patients
in our trial.
Patient education is not provided by all pharmacies
to all patients at each dispensing. A review from 36
studies in the USA, Europe, Australia and Canada
shows that counseling was provided by 50% to 100% of
the pharmacies to 8% to 80% of the patients [3]. The
barriers for implementing patient education in com-
munity pharmacy which we identified from the first
author’s own experience as a pharmacist, from phar-
macists’ reported barriers and facilitators in a previous
trial in which we implemented another pharmaceutical
care service [12] and from the literature [13,14] were:
A) Organizational: making time for introducing patient
education to the pharmacy technicians and for educat-
ing them; lack of time and space for providing patient
education; patients’ privacy; the availability of protocols
for patient education; lack of documentation of patient
education that was provided; lack of reimbursement;
involvement of pharmacy technicians in the implemen-
tation process; B) With regard to the individual profes-
sionals: knowledge and skills of pharmacists and
pharmacy technicians; attitude towards patient educa-
tion; C) Factors concerning the social context: patient
indifference.
Successful implementation of patient education
requires a comprehensive approach, which targets rele-
vant barriers and facilitators to change in a specific set-
ting [15]. Unfortunately, an evidence-based strategy to
translate identified barriers to a tailor-made implemen-
tation intervention is still lacking [16]. So, after having
identified the potential barriers for the implementation
of patient education, we used common sense to design
the intensive implementation intervention, thus follow-
ing the planning model described by Grol and Wensing
[17]. Our intensive multifaceted implementation pro-
gram was directed at pharmacists and at pharmacy tech-
nicians who were appointed as project assistant. This
program consisted of an educational manual, two
interactive educational meetings, reminder and feedback
telephone calls and reminder newsletters.
The aim of the present study was to test the hypoth-
esis that the intensive implementation program would
increase the frequency of patient education provided at
first and second dispensing of statins in community
pharmacies.
Methods
A cluster randomized trial was conducted between Sep-
tember 2006 and February 2008. The medical ethical
committee Arnhem-Nijmegen gave approval for this
trial. The trial consisted of two parts: in the first part,
which is described elsewhere [1], prescribing of statins
for secondary prevention of cardiovascular disease was
targeted. In the second part, which is described here,
the focus was on patient education at the moment
patients presented a statin prescription in a community
pharmacy for the first or second time.
Participants
Community pharmacies were recruited through a mail-
ing to all 211 pharmacies in the South of the Nether-
lands in April 2006. Participation was voluntary, though
encouraged by one of the two major health insurance
companies in this part of the Netherlands: pharmacies
participating in this study were exempted from present-
ing an annual plan and from reporting of patient care
activities. There was no financial incentive for participa-
tion in the project other than the usual dispensing fee
per prescription.
Patients who were selected in the first part of the trial
(which were patients who already used antiplatelet med-
ication but not a statin) and who received a first or a
second statin prescription were eligible for education by
a pharmacist or pharmacy technician.
Randomization
In order to ensure that pharmacies in the control group
would not be influenced by the intensive implementa-
tion program, all pharmacies that cooperated with the
same GPs or that had local collaboration with another
pharmacy in the vicinity were grouped in a cluster of
pharmacies. The clustered pharmacies were numbered
by a research assistant. An independent statistician per-
formed a block randomization, in which the cluster size
(number of pharmacies in each cluster) was balanced.
Interventions
In all pharmacies, both in the control group and in the
experimental group, pharmacists and pharmacy techni-
cians were instructed to provide education at first dis-
pensing (EAFD) and education at second dispensing
(EASD) to new statin users, guided by the same
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protocols for EAFD and EASD. The difference between
the two groups consisted of the way they were sup-
ported with the implementation of EAFD and EASD.
Directed at patients
The protocol for EAFD stated that the pharmacist or
pharmacy technician should read out loud the patient
label including information on the name, strength and
use of the statin, and should explain the importance of
long-term use of the statin to each patient. If the patient
appeared to be interested and if there was enough time,
one or more of the following issues could be discussed
as well: indication of the statin; how it works; side
effects; what to do when a dose intake was missed;
interactions; and if everything was clear to the patient
or whether he or she had any more questions. We
advised the pharmacies not to give too much informa-
tion at first dispensing, because patients generally
receive a lot of information from the physician at the
visit in which they receive their first statin prescription.
The information provided in the pharmacy should be
sufficient to motivate the patient to use the statin at
least until the second dispensing, which is the moment
at which the patient’s experiences with using the medi-
cation are discussed and more information can be
provided.
According to the protocol, EASD (which is normally
two weeks after first dispensing in The Netherlands)
started with the question how the patient had experi-
enced statin use. When the patient had a positive
experience, pharmacists and pharmacy technicians were
instructed to emphasize the importance of long-term
use once more and to mention the possibility to ask
questions about medications in the pharmacy. When the
patient expressed a negative experience, pharmacists
and pharmacy technicians were instructed to find out
whether the patient had any specific questions or pro-
blems and whether they could help the patient with
that.
Directed at pharmacies: experimental group
Experimental pharmacies received a written educational
manual in September or October 2006, which consisted
of information about the project; step-by-step instruc-
tions for carrying out the project; protocols for EAFD
and EASD, an explanation of these protocols and exam-
ples of possible situations at second dispensing for the
pharmacy technicians to practice with; and a flow-chart
for the planning of the project. The project had a
planned duration of 12 months. Pharmacists and phar-
macy technicians who were appointed as project assis-
tant were also invited to an interactive educational
meeting, which was based on the literature [14] and on
the extensive experience of two professional
communication advisors who were well-informed about
daily practice in community pharmacies. After an expla-
nation of the project (what, why, how, by whom, when)
by one of the researchers (CvdS), pharmacists and pro-
ject assistants split up. Pharmacists mainly discussed the
first part of the trial; the project assistants discussed
their experience with EAFD and EASD, and expecta-
tions with regard to this project under the guidance of
two research assistants and guided by a questionnaire.
In a second interactive educational meeting, project
assistants were challenged by a communication advisor
to identify facilitators of implementation and to identify
and tackle potential barriers for implementation with
regard to the content of the protocols; organization of
patient education; and knowledge and motivation of the
pharmacy technicians. In the four reminder telephone
calls which were planned with each pharmacist for the
first part of the trial, the project assistants were also
interviewed and supported with the implementation of
patient education.
Directed at pharmacies: control group
The control group pharmacies received a written educa-
tional manual in October 2006, which was the same as
the manual for the experimental pharmacies. No further
intervention was applied.
Measurements
For each time education was given at first and second
dispensing, the pharmacist or pharmacy technician
marked the items which were discussed on a written
checklist. “EAFD as recommended” included both hav-
ing read out loud the patient label with information on
the name, strength and use of the statin; and having
explained the importance of long-term use. Statin pre-
scriptions for patients who received at least one antipla-
telet drug as well as sex, age and prescriptions for other
cardiovascular drugs or drugs with a statin interaction
were extracted from a national prescription database,
which consists of all dispensing data from more than
1,670 of the 1,850 community pharmacies in the Neth-
erlands. The pharmacies which provide data to this
database serve about 13.5 million people, and dispense
drugs or medical aids some 140 million times per year
(more information at http://www.sfk.nl/algemeen/eng-
lish.html). A statin prescription was considered a first
prescription if there were no statin prescriptions in the
database in the six months before the pharmacy started
the first part of the trial. Follow-up data on statin use
were available until February 2008. Pharmacy character-
istics were measured at the start of the study by means
of a written inventory. Barriers and facilitators with
regard to the implementation process in the experimen-
tal pharmacies were collected by means of the telephone
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interviews which were part of the intensive implementa-
tion program.
Outcomes
The primary outcome of the study was the percentage
of patients with a first prescription for a statin who
received EAFD. The secondary outcome of the study
was the percentage of patients with a second prescrip-
tion for a statin who received EASD. Additional out-
comes were perceived barriers and facilitators to
implementation in the intervention group and the effect
of EAFD and EASD on persistence with statin therapy.
Sample size
Because this was the sequel of a trial which was
designed to enhance statin prescribing for patients with
cardiovascular disease, the sample size needed was not
calculated for the primary outcome of this study, but for
the primary outcome of the first part of the trial. We
planned to include 7980 patients from 76 pharmacies.
Statistical analysis
The impact of the intensive implementation program on
the implementation process and on the primary out-
comes was examined in a random coefficient logistic
regression model, which took into account that patients
were grouped within pharmacy clusters. The primary
analysis was quasi intention-to-treat [18] and involved
all patients of whom statin dispensing data were known.
P-values of 0.05 or less were considered significant.
Determinants for providing EAFD were tested for using
unpaired t-tests and Chi-squared tests. Data were ana-
lyzed using the SPSS 16.0 software package, except the
random coefficient logistic regression analysis, which
was performed using the SAS 9.1.3 software by means
of the Glimmix procedure.
Results
Participating pharmacies, loss to follow-up and data
completeness
The flow of participants throughout the study is shown
in Figure 1. In total, 71 eligible pharmacies registered
for participation in the study between May and August
2006, which were grouped into 36 clusters (taking into
account local collaborations). Randomization resulted in
a control group of 34 pharmacies in 18 pharmacy clus-
ters and an experimental group of 37 pharmacies in 18
pharmacy clusters.
Six pharmacies withdrew between September and
November 2006: three of them were closed for ever; two
had changed priorities; and one pharmacy did not
respond to repeated attempts to obtain information.
Patient data at baseline and follow-up were available for
52 pharmacies: one pharmacy did not give authorization
to the national database administrator for data extrac-
tion; one pharmacy had opened in October 2005 and
did not have 12 complete months of patient data before
the start of the project, which was required for the first
part of the trial; and for 11 pharmacies data extraction
was impossible because patient identification numbers
changed during the project due to a switch of the phar-
macy to another computer system.
In the 52 pharmacies for which patient data were
available, 871 of the selected patients were eligible for
EAFD since they received a first statin prescription
within 12 months after the start of the project and 735
patients also received a second statin prescription,
which made them eligible for EASD as well.
Success of the implementation
The indicators for success of the implementation are
shown in Table 1. In the control group, 14 pharmacies
(45.2%) did provide EAFD and 12 pharmacies (38.7%)
did provide EASD, respectively, versus 17 pharmacies
(50.0%, P = 0.715) and 12 pharmacies (35.3%, P =
0.899), respectively, in the experimental group. There
were no differences between the two groups in the pri-
mary or in the secondary outcome: 78 patients (19.4%)
with a first statin prescription received EAFD and 35
patients (10.2%) received EASD in the control group,
versus 72 patients (15.5%, P = 0.944) and 49 patients
(12.5%, P = 0.579) in the experimental group. Also, the
percentage of new users who received EAFD in the
pharmacies which did implement EAFD was similar in
both groups. The pharmacy which performed best,
offered EAFD and EASD to 15 of the 19 patients
(78.9%) who received a first statin prescription after the
pharmacy had started providing EAFD. The Intracluster
correlation coefficient (ICC) for the primary outcome
was 0.347. In the pharmacies which did provide EASD
to at least one patient, a higher percentage of the new
statin users received EASD in the experimental group,
but this difference did not reach significance: 28.2% ver-
sus 17.1% in the control group (P = 0.172) in the multi-
level analysis.
Table 2 shows the content of education in subjects who
received education at first dispensing. The patient label
was read out loud at first dispensing more frequently in
the experimental group than in the control group (86.1%
versus 69.2%, P = 0.017), and more patients received
EAFD on the indication for the statin in the experimental
group (77.8% versus 59.0%, P = 0.016).
In Table 3 the pharmacy characteristics related to
education at first dispensing are shown (see also,
Appendix). None of the pharmacy characteristics was
significantly related to providing EAFD.
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Barriers and facilitators
The barriers and facilitators for implementing education at
first and second dispensing, reported by the project assis-
tants in the experimental group, are shown in Table 4.
The main barrier was that the pharmacist chose (either
explicitly or implicitly) not to start with EAFD and EASD:
In three pharmacies the project had discontinued comple-
tely, in five pharmacies the pharmacist did not want to
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Figure 1 Participant flow.
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start before the general practitioners had reviewed and
returned the list with selected patients on which they had
marked the patients with a statin indication, which was
late or did not happen at all. In five other pharmacies, the
pharmacist did not take much initiative to retrieve the lists
or to start with EAFD and EASD, according to the project
assistants. The project assistant and other pharmacy tech-
nicians were discouraged by that. Other barriers with
regard to the implementation were insufficient staff (5×);
negative reactions from patients (4×); lack of routine
because of the limited number of new statin users (2×);
lack of experience with EASD (2×); forgetting to fill in the
checklist sometimes (2×); other priorities in the pharmacy
(1×); and difficulties with opening a conversation at the
moment of second dispensing (1×).
Perceived facilitators were enthusiastic pharmacy tech-
nicians (8×); pharmacy technicians who were used to
providing EAFD and/or EASD (7×); positive reactions of
patients (5×); project materials (2×); computer reminder
at the moment of first or second dispensing (2×);
patients were informed before they visited the pharmacy
by a general practitioner or by means of a letter (2×);
pharmacist gave feedback to pharmacy technicians (1×);
materials on a visible place (1×); EAFD and EASD fitted
well into the regular work system (1×). Pharmacies
which performed best in this study did not report
Table 2 Content of education in patients or patient representatives who received education at first dispensing
Experimental group (N = 72) Control group (N = 78) P-value
Patient himself/herself fetched medication and was interested 49 (68.1) 47 (60.3) 0.323
Patient label read out loud a;b 62 (86.1) 54 (69.2) 0.017
Importance of long-term use a 53 (73.6) 47 (60.3) 0.098
Indication of the statin 56 (77.8) 46 (59.0) 0.016
How statin works 44 (61.1) 45 (57.7) 0.661
Side effects 47 (65.3) 48 (61.5) 0.636
What to do when a dose intake is missed 20 (27.8) 24 (30.8) 0.577
Interactions 20 (27.8) 27 (34.6) 0.352
Contact for more information 33 (45.8) 36 (46.2) 0.931
At least one of these 65 (90.3) 55 (70.5) 0.006
Both subjects which were recommended in protocol EAFD 51 (70.8) 47 (60.3) 0.179
EAFD, education at first dispensing
Data are absolute frequencies, with the percentage between brackets.
a Recommended in the protocol for education at first dispensing
b The patient label includes information on the name, strength and use of the statin.
Table 1 Indicators for success of implementation
Experimental
group
Control
group
OR (95%
CI)
P-
value
Frequency of EAFD offered (% of first prescriptions) a 72/469 (15.4) 78/402 (19.4) 0.96
(0.31;3.01)
0.944
Number of pharmacies which offered EAFD (%) 17/34 (50.0) 14/31 (45.2) 1.24
(0.38;4.00)
0.715
Frequency of EAFD offered in the pharmacies which performed EAFD (% of first
prescriptions) b
72/252 (28.6) 78/257 (30.4) 1.08
(0.51;2.29)
0.845
Frequency of EASD offered (% of second prescriptions) a 49/393 (12.5) 35/342 (10.2) 1.41
(0.42;4.78)
0.579
Number of pharmacies which offered EASD (%) 12/34 (35.3) 12/31 (38.7) 0.93
(0.27;3.20)
0.899
Frequency of EASD offered in the pharmacies which did perform EASD (% of second
prescriptions) c
49/174 (28.2) 35/205 (17.1) 1.85
(0.76;4.50)
0.172
EAFD, education at first dispensing; EASD, education at second dispensing; OR, odds ratio
a Data from the pharmacies of which the total number of first statin prescriptions was known, which were 25 pharmacies in the control group and 27
pharmacies in the experimental group.
b Data from the pharmacies which did perform EAFD and of which the total number of first statin prescriptions was known: 12 pharmacies in the control group
and 13 pharmacies in the experimental group.
c Data from the pharmacies which did perform EASD and of which the total number of second statin prescriptions was known: 10 pharmacies in the control
group and 10 pharmacies in the experimental group.
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obviously different barriers or facilitators than pharma-
cies which did not perform well.
Effect of education at first and second dispensing
Table 5 shows the use of statins related to whether
patients received education at first or second dispensing
as recommended by the study protocol. In the group of
patients who did receive EAFD as recommended, signifi-
cantly more patients received a second statin prescrip-
tion: 93.9% versus 83.2% in the group of patients who
did not receive EAFD as recommended (P = 0.028). The
difference was no longer significant after 6 months:
80.7% of the patients who did receive EAFD as recom-
mended used the statin for at least 6 months versus
77.0% of the patients who did not receive EAFD as
recommended (P = 0.867). A non-significant difference
was also found between patients who did versus patients
who did not receive EASD: 91.2% of the patients in the
first group still used the statin after 6 months, versus
83.2% of the patients in the second group (P = 0.216).
Discussion
Only half of all pharmacies provided EAFD to at least
one patient and in the pharmacies which did, less than
one third of the patients received EAFD on average.
Apparently, the intensive implementation program was
not able to overcome the main barriers or to enhance
factors needed for providing EAFD and EASD to new
statin users. Pharmacies in the intervention group did
not provide more education to patients at first or sec-
ond dispensing of statins compared to the pharmacies
in the control group. A review of 36 studies on patient
education on medication [3] indicated that 29-87% of
pharmacists or other pharmacy staff counselled 40-69%
of all patients with a prescription for new medication.
So, the finding that half of the pharmacies provided
patient education in our study is similar to previous
findings, but the percentage of new statin users receiv-
ing EAFD in our study was low compared to other
research.
None of the characteristics which were related to the
pharmacy’s care providing function in previous studies
[12,19] or of the other factors we investigated was
related to providing EAFD. It is remarkable that being
used to providing EAFD as reported by the pharmacist
at the start of the study, did not influence the frequency
of EAFD provided in this study. Nevertheless, seven pro-
ject assistants from the experimental group sponta-
neously reported it as a facilitator for implementation.
Possibly, the extent to which EAFD was provided in the
participating pharmacies before we started the study,
was of importance. For patient education on the nega-
tive effects of benzodiazepines, Ten Wolde et al. [20]
reported that pharmacists’ intention to provide educa-
tion was higher if they expected more positive outcomes
and if they experienced stronger social pressure to pro-
vide education. It is very well possible that pharmacists’
intention to provide EAFD and EASD in our study may
Table 3 Characteristics of pharmacies related to education at first dispensing
Pharmacies which did educate
patients at first dispensing
(N = 31a)
Pharmacies which did not educate
patients at first dispensing
(N = 34)
P-value
Number of years in service pharmacist b 16.5 ± 9.0 14.5 ± 8.5 0.382
Frequency of postgraduate training in pharmacotherapy for
pharmacist: Regularly or Often
28 (90.3) 32 (94.1) 0.566
Attitude regarding care-providing function (continuous scale
of 16-80) b;c
66.2 ± 6.6 66.3 ± 6.6 0.969
Pharmacy technicians with specialized care-providing duties 18 (58.1) 23 (67.6) 0.424
Relationship with GP: Good or very good 22 (71.0) 19 (55.9) 0.208
Workload as perceived by pharmacist: High or very high 10 (32.3) 10 (29.4) 0.804
Pharmacy is part of chain or franchise formula 21 (67.7) 22 (64.7) 0.796
Participation in study because of perception of pressure from
insurance company: Partly or completely agree
5 (16.1) 6 (17.6) 0.870
Number of first statin prescriptions within 6 months of start
of the project
11.7 ± 8.0 7.9 ± 7.3 0.082
Team was used to providing education at first dispensing of
(some types of) medication
30 (96.8) 30 (88.2) 0.197
GP, general practitioner
Data are absolute scores (% in brackets) unless otherwise specified
a 17 pharmacies from the experimental group and 14 pharmacies from the control group
b Data are mean scores ± SD
c Attitude was measured using the statements which are described in the Appendix
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have influenced the implementation. A substantial num-
ber of pharmacies started late or not at all, with EAFD
and EASD, because pharmacists waited for GPs to have
checked the selected patients for an actual statin indica-
tion. Possibly, some pharmacists were not only rather
passive in retrieving the lists from general practitioners,
but in managing the team of pharmacy technicians as
well. It is remarkable that pharmacies in which project
assistants reported very positively about enthusiastic
pharmacy technicians as a facilitator for implementation,
did not necessarily provide more EAFD and EASD.
Whether the intensive implementation strategy should
have been directed not mainly at the project assistants,
but also more at the pharmacists, will be a topic for
further research.
In the pharmacies which started late with EAFD and
EASD, patients might have received a statin before the
pharmacy had started providing education. If we had
Table 4 Barriers and facilitators for the implementation of EAFD and EASD reported by project assistants of
experimental pharmacies
Barriers related to the: Influenced which step of
implementation process
Frequency of reporting (number of
pharmacies)
Individual professionals
Lack of pharmacist’s initiative to start with EAFD and EASD Getting started 8
Pharmacist wanted to wait for list returned from GPs Getting started 5
Forgetting to fill in the checklist sometimes Registration 2
Difficulties with opening a conversation at the moment of
second dispensing
Getting started and continuation 1
Organizational context
Insufficient staff Getting started 5
Lack of routine because of limited number of new statin
users
Continuation 2
Lack of experience with EASD Getting started 2
Other priorities in pharmacy Getting started 1
Patients
Negative reactions of patients Continuation 4
Facilitators related to the:
Individual professionals
Enthusiastic pharmacy technicians Getting started 8
Organizational context
Pharmacy technicians used to providing EAFD and/or
EASD
Getting started 7
Availability of project materials Getting started 2
Computer reminder at the moment of first or second
dispensing
Continuation 2
Patients were informed already by GP Continuation 2
Feedback to pharmacy technicians by pharmacist Continuation 1
Materials on a visible place Continuation 1
EAFD and EASD fits well into regular work system Continuation 1
Patients
Positive reactions of patients Continuation 5
Table 5 Use of statins related to receiving education at dispensing
Yes No P-
value
Number of patients who received a second statin prescription (%) related to whether they had received EAFD as
recommended (yes/no)
92/98
(93.9)
643/773
(83.2)
0.028
Number of patients who still used a statin 6 months after first dispensing (%) related to whether they had received
EAFD as recommended (yes/no) a
71/88
(80.7)
435/565
(77.0)
0.867
Number of patients with a second statin prescription who still used a statin 6 months after first dispensing (%) related
to whether they had received EASD (yes/no) a
73/80
(91.2)
421/506
(83.2)
0.216
a Data from patients with at least 6 months follow up after first dispensing.
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only taken into account the patients who received a sta-
tin after the pharmacies had started with EAFD, than
we would have found that more than one third of them
did receive EAFD, which is still a low percentage. The
low number of first statin prescriptions may also have
contributed to the limited provision of EAFD and EASD
in both groups, because enough exposure is needed for
pharmacy technicians to become skilled in providing a
new service. However, in most pharmacies the pharmacy
technicians were already used to providing patient edu-
cation at first dispensing of (some types of) medication.
Finally, the measurement of the provision of EAFD and
EASD by means of point of care checklists that were
filled in manually may have caused underreporting of
EAFD and EASD.
Although the intensive implementation program did
not succeed in a better implementation of EAFD and
EASD, it did have some effect on two elements of EAFD
and EASD. Pharmacies in the experimental group
appear to have chosen to focus on three aspects of
EAFD, even if the patient did not fetch the medication
himself/herself: read out loud the patient label with
information about correct use; the indication for the sta-
tin; and the importance of its long-term use. This largely
complies with the recommendation in the protocol for
EAFD, which was also a subject in the second interac-
tive educational meeting as a part of the intensive
implementation strategy. Additionally, in the pharmacies
who implemented EAFD and EASD, significantly more
patients in the experimental group received EASD com-
pared to patients in the control group. Experimental
pharmacies provided EASD as frequently as they pro-
vided EAFD.
At the time this study was designed, providing EAFD
and EASD was expected to improve medication adher-
ence and persistence, even though the evidence for that
was still lacking. This study was not designed to examine
the effect of EAFD and EASD on statin persistence, so
the results - which indicate a possible positive effect of
EAFD on the short term - should be interpreted with
caution. Possibly, there were differences in the quality of
patient education between the control group and the
experimental group, or differences in the education GPs
had already given to their patients which could have
attributed to the improved adherence in the experimental
group. About 15% of the new statin users did not receive
a second prescription, which indicates that use of statins
rapidly decreases in an early stage, with a gradually smal-
ler decrease on the longer term. This is in line with pre-
vious research [6]. In the meanwhile, several studies have
been performed to investigate the effect of patient educa-
tion on patients’ adherence and persistence with statins.
In general, interventions for improving adherence with
chronic medication that have been shown to be effective
are complex and do not lead to large improvements in
adherence [21]. Studies which were published more
recently have shown that simple interventions have not
been able to increase patients’ adherence with statins [22]
or with other medicines for chronic use, among others
lipid modifying agents [23]. A more extensive form of
patient education, which existed of brief counselling by a
physician followed by patient education mailings, has
been shown to increase adherence with statins after four
months [24]. Another intensive program has been shown
to improve statin taking for at least one and a half year
after cessation of the program [25], whereas another
intensive program has been shown only to improve lipid
levels in new statin users at three and six months after
the start of the program, but not after one year [26].
Note that all residents in The Netherlands have an obli-
gatory health insurance, which covers most medication.
At the time of the study, there was no policy excess yet.
So, out-of-pocket cost will not have hampered medica-
tion adherence in this study.
The randomized design was a strength of our study,
although the statistical power was not focused on the
outcomes reported here. As the pharmacies did not
include the expected number of new statin users the
number of patients included in this second part of the
study remained low. It is possible that the intensive
implementation program would have been more effec-
tive if more GPs would have cooperated actively in the
first part of the trial and if more patients would have
received a first statin prescription. Another weakness
included the manual registration of EAFD and EASD by
the pharmacy technicians. Occasionally they may have
forgotten to complete the checklists, which may have
led to underreporting of EAFD and EASD. On the other
hand, manual registration at each first or second dispen-
sing had the advantage that it was an objective measure
and that recall bias could be avoided. By only using the
checklists, we did not have any information on the qual-
ity of education provided.
Conclusions
The intensive implementation program has not been
able to increase the frequency of patient education pro-
vided at first and second dispensing of statins in com-
munity pharmacies, but it did accomplish that more
patients received EASD in the pharmacies that imple-
mented EASD. It remains unclear which factors contri-
bute to successful implementation of EAFD and EASD.
Although this study was not designed to investigate the
effect of EAFD and EASD on statin adherence and per-
sistence, the results indicate a possible positive effect on
short term.
Because patient education is a basic element of phar-
maceutical care, more efforts are required to implement
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EAFD and EASD on a large scale. Also, more research is
needed to evaluate which factors influence their imple-
mentation and to develop a more effective implementa-
tion strategy. The effect of EAFD and EASD on patients’
persistence with medication should be evaluated as well.
Appendix
Attitude was measured using the construct developed by
Muijrers et al [19]:
1. Pharmacists are the major medication experts in
primary care.
2. The pharmacist should play a very important role in
the care for patients who are actively using drugs.
3. Pharmacists greatly influence the use of medication.
4. The pharmacist should play a very important role in
the drug prescription policy of the general practitioner.
5. Being a pharmacist, I hardly have any influence on
the drug prescription policies of the general practi-
tioners in my area of care.
6. To a major extent, the pharmacist is co-responsible
for the drug therapy of his pharmacy’s patients.
7. If a general practitioner is not sure about which
drug therapy is most suitable for a given patient, the
general practitioner should contact the pharmacist for
advice.
8. When trying to make agreements within the PTAM
group, the input of the pharmacist is essential.
9. The pharmacist should contribute to the PTAM
agenda by supplying information about the prescription
patterns observed in his/her pharmacy.
10. It is the task of the pharmacist to provide feedback
to general practitioners with regard to their prescription
figures.
11. The only responsibility of the pharmacist is to dis-
tribute drugs (i.e. providing the drug plus a brief
instruction to the patient on how to use it, as well as
monitoring potentially harmful interactions with other
drugs).
12. The pharmacist should be aware of all the diag-
nosed conditions of a given patient which may affect
medication response.
13. The pharmacist should be allowed to provide a
pharmacotherapeutic substitute (i.e. an analogous drug,
rather than the prescribed drug, is provided to the
patient).
14. The pharmacist should be authorized to provide
repeat-medication independently of the general
practitioner.
15. It is the responsibility of the pharmacist to docu-
ment undesirable prescription patterns of general
practitioners.
16. In her/his role as medication expert, the pharma-
cist is responsible for the consequences of providing
irrational drug therapy.
The following statement was omitted from this con-
struct, because this is everyday practice in the
Netherlands.
17. The pharmacist should be allowed to provide a
generic drug instead of a prescribed specialty drug.
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